CG
NBIX icon

Caprock Group’s Neurocrine Biosciences NBIX Stock Holding History

Caprock Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$311K Buy
+2,357
New +$313K 0.01% 907
2025
Q1 		$259K Buy
2,346
+619
+36% +$78.4K 0.01% 921
2024
Q4 		$236K Buy
+1,727
New +$214K 0.01% 880
2024
Q3 		– Sell
-1,669
Closed -$230K – 954
2024
Q2 		$230K Buy
1,669
+109
+7% +$14.9K 0.01% 765
2024
Q1 		$215K Buy
+1,560
New +$213K 0.01% 659
2018
Q3 		– Sell
-2,712
Closed -$266K – 430
2018
Q2 		$266K Sell
2,712
-11
-0.4% -$985 0.06% 318
2018
Q1 		$226K Buy
+2,723
New +$230K 0.05% 358

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caprock Group's NBIX Position: Q1 2026 in Review

Caprock Group opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 2,357 shares worth $311K. The stake represents 0.01% of the portfolio and ranks #907 among its holdings. This is a return to the name: Caprock Group previously reported a position in NBIX as recently as Q1 2025.

Caprock Group first reported a position in NBIX in Q1 2018 and has held it in 7 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Caprock Group held 2,357 shares of Neurocrine Biosciences worth $311K as of Q1 2026.
  • Neurocrine Biosciences was a new Caprock Group position in Q1 2026.
  • Neurocrine Biosciences made up 0.01% of Caprock Group's portfolio in Q1 2026, its #907 holding.
  • Caprock Group first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 7 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.